Erasca, Inc. (ERAS) News
Filter ERAS News Items
ERAS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ERAS News Highlights
- ERAS's 30 day story count now stands at 3.
- Over the past 12 days, the trend for ERAS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ALTO and ESP are the most mentioned tickers in articles about ERAS.
Latest ERAS News From Around the Web
Below are the latest news stories about Erasca Inc that investors may wish to consider to help them evaluate ERAS as an investment opportunity.
Is a Surprise Coming for Erasca (ERAS) This Earnings Season?Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology DaySAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat beginning a |
Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ...Investment company Edmonds Duncan Registered Investment Advisors, LLC (Current Portfolio) buys VanEck Vectors Semiconductor ETF, Erasca Inc, Concentrix Corp, Tenet Healthcare Corp, Palo Alto Networks Inc, sells WisdomTree Japan Hedged Equity Fund, PayPal Holdings Inc, Alphabet Inc, Boeing Co, Walmart Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Edmonds Duncan Registered Investment Advisors, LLC. |
Erasca Strengthens Leadership Team with Two Key Executive AppointmentsLisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice Presi |
Erasca to Present at the 40th Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 40th annual J.P. Morgan Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company and pipeline at 3:45 pm Eastern Time on Monday, January 10, 2022. Dr. Li |
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc. |
Erasca (NASDAQ:ERAS) Shares Gap Up to $13.65Erasca Inc (NASDAQ:ERAS)s share price gapped up prior to trading on Friday . The stock had previously closed at $13.65, but opened at $14.32. Erasca shares last traded at $14.47, with a volume of 111 shares. Separately, Zacks Investment Research lowered Erasca from a hold rating to a sell rating in a research note on [] |
Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical TrialIND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022 |
VIP Health Care Portfolio Buys Thermo Fisher Scientific Inc, Royalty Pharma PLC, Charles River ...Investment company VIP Health Care Portfolio (Current Portfolio) buys Thermo Fisher Scientific Inc, Royalty Pharma PLC, Charles River Laboratories International Inc, Alignment Healthcare Inc, Twist Bioscience Corp, sells Bristol-Myers Squibb Co, Regeneron Pharmaceuticals Inc, Novavax Inc, Anthem Inc, Turning Point Therapeutics Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, VIP Health Care Portfolio. |
How Much Of Erasca, Inc. (NASDAQ:ERAS) Do Insiders Own?Every investor in Erasca, Inc. ( NASDAQ:ERAS ) should be aware of the most powerful shareholder groups. Large companies... |